Vertex Pharma (VRTX) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
No Surprises from Vertex (VRTX) But Piper Jaffray Moves Price Target Down to $143
January 28, 2016 7:25 AM ESTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating but lowered his price target on Vertex (NASDAQ: VRTX) to $143.00 (from $180.00) following results which offered no surprises.
Tenthoff commented, "As pre-announced, >4,500 patients began ORKAMBI in the U.S. resulting in sales of $220 million in 4Q:15;... More
